Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis Extends Alnylam’s RNAi Therapeutics Collaboration
Novartis has extended the Alnylam’s RNAi therapeutics collaboration for a fifth and final planned year, through October 2010. The alliance was initiated in October 2005, and is focused
Novartis has extended the Alnylam’s RNAi therapeutics collaboration for a fifth and final planned year, through October 2010. The alliance was initiated in October 2005, and is focused
Actelion has obtained positive result in a phase IIa study, with orally active non-prostanoid PGI2 receptor agonist in pulmonary arterial hypertension (PAH) patients. In the 43 patient placebo-controlled
Castle Biosciences, a Texas-based cancer diagnostics company, has unveiled DecisionDx-GBM, a molecular brain cancer diagnostic test. It is developed at and licensed from The University of Texas M.
Cubist Pharmaceuticals has reported an increase in total sales revenue by 28% for the second quarter of 2009 to $130.8 million, as compared to $101.8 million in the
Ambrilia and Kotinos have signed a Patent and Technology Purchase agreement, whereby Kotinos will acquire Ambrilia’s prostate cancer therapeutic PCK3145 and related assets. Under the agreement, Ambrilia is
With immediate effect, Bayer MaterialScience has lifted force majeure for the polyurethane raw material toluene diisocyanate (TDI) in Europe, the Middle East, Africa (EMEA) region. The damage to
Sanofi Pasteur has received an order from the French Ministry of Health to produce a vaccine against the A(H1N1) influenza virus. The company is set to produce initial
AstraZeneca and the Mental Health Research Institute in Australia have entered into a research collaboration agreement, to develop new ways of identifying Alzheimer’s disease patients at early stages
BiPar has initiated the pivotal phase 3 trial for BSI-201 in combination with chemotherapy. The trial is on patients with metastatic triple-negative breast cancer (mTNBC), defined by tumors
Angiotech Pharmaceuticals has received approval from the US Food and Drug Administration (FDA), to market its TAXUS Liberte Long Paclitaxel-Eluting Coronary Stent System. Its a next-generation drug-eluting stent